Background: PML, caused by polyomavirus JC (JCV), remains a severe opportunistic disease in HIV-infected patients. Detection of JCV-DNA in plasma and peripheral leukocytes has been reported in immunocompromised subjects, with or without PML, but it was neither regarded as a sensitive and specific diagnostic marker of PML. Moreover, it is not known whether it can be considered as a marker of more aggressive PML course. The aim of this study was to assess the diagnostic and prognostic significance of JCV-DNA levels in plasma at PML onset on clinical outcome. Methodology: This is a cross-sectional, retrospective, multicentre study of 79 patients with HIV-related PML and 49HIV positive controls whose plasma samples were collected within 90 days from onset of symptoms and available for virological analysis. Patients were enrolled in Italy between 1993 and 2012. PML diagnosis was confirmed by JCV-DNA detection in CSF in 68 cases, at autopsy in 2 cases, or based on typical clinical and radiological features in 9 cases. Associations between categorical measures were assessed by the Fisher’s exact test. The effect of a number of factors on time from onset of symptoms to the end of follow-up due to progressive disease or death was assessed by Kaplan-Meier and Cox proportional-hazard models. Results: Sixteen/79 patients (20.3%) were female and 63 (79.7%) male, median (IQR) age was 38 years (34-43.5), CD4+ were 80 (38-220) cells/μL, plasma HIV-RNA was 3.87 (1.69-4.98) log10 copies/mL at the time of PML and 59/79 (74%) were exposed to combined antiretroviral treatment (cART). Fifteen patients showed contrast enhancement at magnetic resonance imaging, 12 experienced immune reconstitution inflammatory syndrome (IRIS), and 10 received high-dose steroids. JCV-DNA was detected in plasma of 4/49 (0.1%) control subjects and of29/79 (36%) PML patients. The sensitivity and specificity of the presence of JCV-DNA in plasma was36.7% and 91.8%, respectively. The only independent factor associated with JCV-DNAdetection in plasma was JCV-DNA in CSF. The occurrence of IRIS was associated with more favourable clinical outcome. cART therapy was associated with an 8-fold reduction in the hazard of progression or death among patients without JCV-DNA in the plasma (p=0.003) but only a 3-fold reduction among patients with JCV-DNA in plasma (p=0.005) and patients with JCV-DNA in CSF (p=0.012). Conclusions: Detection of JCV-DNA in plasma has low sensitivity but high specificity in PML diagnosis. Presence of JCV-DNA in plasma is associated with a less favorable clinical outcome in patients with PML. Although cART is associated with dramatic reductions in the hazard of progression or death from PML, its effect is attenuated when JCV-DNA is not suppressed in plasma.